Pathology service provider ProPath selects CombiMatrix (CBMX) to "provide its chromosomal microarray analysis testing for miscarriage analysis."
"For an important group of patients, CMA testing can play a significant role in a comprehensive miscarriage analysis," a ProPath director notes.
CBMX says the agreement is "yet another validation of the quality of [its] diagnostic services." (PR)
CBMX +14% premarket.